U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11F2N3O4
Molecular Weight 263.1981
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GEMCITABINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf

Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA. Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

CNS Activity

Curator's Comment: modest penetration of gemcitabine into the CSF after i.v. administration in nonhuman primates was shown, also can partially cross the BBB in humans https://www.ncbi.nlm.nih.gov/pubmed/17538177

Originator

Curator's Comment: # Eli Lilly; University of Innsbruck

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL614774
3.0 nM [IC50]
Target ID: CHEMBL614067
30.0 nM [IC50]
Target ID: CHEMBL614139
10.0 nM [IC50]
7.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Gemzar

Approved Use

Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer.

Launch Date

8.3203201E11
Primary
Gemzar

Approved Use

Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer.

Launch Date

8.3203201E11
Primary
Gemzar

Approved Use

Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer.

Launch Date

8.3203201E11
Primary
Gemzar

Approved Use

Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer.

Launch Date

8.3203201E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
229 nM
75 mg/m² 1 times / week multiple, intravenous
dose: 75 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
263.6 nM
135 mg/m² 1 times / week multiple, intravenous
dose: 135 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
292.5 nM
180 mg/m² 1 times / week multiple, intravenous
dose: 180 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3526.4 nM × h
75 mg/m² 1 times / week multiple, intravenous
dose: 75 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4818.5 nM × h
135 mg/m² 1 times / week multiple, intravenous
dose: 135 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4863.4 nM × h
180 mg/m² 1 times / week multiple, intravenous
dose: 180 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
GEMCITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5700 mg/m2 1 times / 2 weeks multiple, intravenous
MTD
Dose: 5700 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 5700 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 55 years (range: 34-71 years)
n = 4
Health Status: unhealthy
Age Group: 55 years (range: 34-71 years)
Sex: M+F
Population Size: 4
Sources:
Other AEs: Myelosuppression, Paresthesia...
2200 mg/m2 3 times / 4 weeks multiple, intravenous
MTD
Dose: 2200 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2200 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 6
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 6
Sources:
Other AEs: Neutropenia, AST increased...
Other AEs:
Neutropenia (grade 2, 1 patient)
AST increased (grade 2, 1 patient)
ALT increased (grade 2, 1 patient)
Sources:
2800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 2800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 5
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 5
Sources:
DLT: Hepatotoxicity, Neutropenic infection...
Dose limiting toxicities:
Hepatotoxicity (grade 3, 2 patients)
Neutropenic infection (grade 4, 1 patient)
Sources:
1000 mg/m2 3 times / 4 weeks multiple, intravenous
Recommended
Dose: 1000 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 74 years
n = 1
Health Status: unhealthy
Age Group: 74 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Necrosis skin...
AEs leading to
discontinuation/dose reduction:
Necrosis skin (1 patient)
Sources:
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Disc. AE: Myocardial infarction, Cerebrovascular accident...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction (2%)
Cerebrovascular accident (2%)
Arrhythmia (2%)
Hypertension (2%)
Anemia (<1%)
Thrombocytopenia (<1%)
Hepatic dysfunction NOS (<1%)
Kidney dysfunction (<1%)
Nausea (<1%)
Vomiting (<1%)
Fever (<1%)
Rash (<1%)
Dyspnea (<1%)
Hemorrhage (<1%)
Infection (<1%)
Stomatitis (<1%)
Somnolence (<1%)
Flu syndrome (<1%)
Edema (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Myelosuppression
5700 mg/m2 1 times / 2 weeks multiple, intravenous
MTD
Dose: 5700 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 5700 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 55 years (range: 34-71 years)
n = 4
Health Status: unhealthy
Age Group: 55 years (range: 34-71 years)
Sex: M+F
Population Size: 4
Sources:
Paresthesia
5700 mg/m2 1 times / 2 weeks multiple, intravenous
MTD
Dose: 5700 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 5700 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 55 years (range: 34-71 years)
n = 4
Health Status: unhealthy
Age Group: 55 years (range: 34-71 years)
Sex: M+F
Population Size: 4
Sources:
Rash severe
5700 mg/m2 1 times / 2 weeks multiple, intravenous
MTD
Dose: 5700 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 5700 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 55 years (range: 34-71 years)
n = 4
Health Status: unhealthy
Age Group: 55 years (range: 34-71 years)
Sex: M+F
Population Size: 4
Sources:
ALT increased grade 2, 1 patient
2200 mg/m2 3 times / 4 weeks multiple, intravenous
MTD
Dose: 2200 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2200 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 6
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 6
Sources:
AST increased grade 2, 1 patient
2200 mg/m2 3 times / 4 weeks multiple, intravenous
MTD
Dose: 2200 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2200 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 6
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 6
Sources:
Neutropenia grade 2, 1 patient
2200 mg/m2 3 times / 4 weeks multiple, intravenous
MTD
Dose: 2200 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2200 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 6
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 6
Sources:
Hepatotoxicity grade 3, 2 patients
DLT
2800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 2800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 5
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 5
Sources:
Neutropenic infection grade 4, 1 patient
DLT
2800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 2800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 2800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 58 years (range: 40-77 years)
n = 5
Health Status: unhealthy
Condition: Non-Small-Cell Lung Cancer
Age Group: 58 years (range: 40-77 years)
Sex: M+F
Population Size: 5
Sources:
Necrosis skin 1 patient
Disc. AE
1000 mg/m2 3 times / 4 weeks multiple, intravenous
Recommended
Dose: 1000 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 1000 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, 74 years
n = 1
Health Status: unhealthy
Age Group: 74 years
Sex: M
Population Size: 1
Sources:
Arrhythmia 2%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Cerebrovascular accident 2%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Hypertension 2%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Myocardial infarction 2%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Anemia <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Dyspnea <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Edema <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Fever <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Flu syndrome <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Hemorrhage <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Hepatic dysfunction NOS <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Infection <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Kidney dysfunction <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Nausea <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Rash <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Somnolence <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Stomatitis <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Thrombocytopenia <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Vomiting <1%
Disc. AE
800 mg/m2 3 times / 4 weeks multiple, intravenous
Dose: 800 mg/m2, 3 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 800 mg/m2, 3 times / 4 weeks
Sources:
unhealthy, adult
n = 979
Health Status: unhealthy
Condition: malignancies
Age Group: adult
Sex: M+F
Population Size: 979
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as victim
PubMed

PubMed

TitleDatePubMed
Treatment of classical Kaposi's sarcoma with gemcitabine.
2001
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.
2001
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
2001
Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.
2001
Malignant pleural mesothelioma.
2001
Treatment of extensive stage small cell lung cancer.
2001
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
2001
Chemoradiation in locally advanced non-small cell lung cancer.
2001
Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.
2001 Apr
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
2001 Feb
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
2001 Feb
[Palliative therapy of pancreatic adenocarcinoma].
2001 Feb
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
2001 Feb
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
2001 Feb
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
2001 Feb
Gemcitabine and Pemetrexed disodium in treating breast cancer.
2001 Feb
Gemcitabine plus cisplatin in breast cancer.
2001 Feb
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
2001 Feb
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
2001 Feb
Treatment of advanced breast cancer with gemcitabine and vinorelbine.
2001 Feb
Gemcitabine as single-agent therapy in the management of advanced breast cancer.
2001 Feb
Chemotherapy agents in transitional cell carcinoma: the old and the new.
2001 Feb
Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.
2001 Feb
The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.
2001 Feb
The clinical implications of gemcitabine radiosensitization.
2001 Feb
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
2001 Feb 1
End-joining deficiency and radiosensitization induced by gemcitabine.
2001 Feb 15
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
2001 Feb 15
Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings.
2001 Jan
Phase I trial of gemcitabine in patients with advanced pancreatic cancer.
2001 Jan
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
2001 Jan
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
2001 Jan
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
2001 Jan
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
2001 Jan
Combined use of gemcitabine and radiation in mice.
2001 Jan-Feb
Novel approaches in the treatment of non-small-cell lung cancer.
2001 Mar
Gemcitabine and nonplatinum combinations in non-small-cell lung cancer.
2001 Mar
Gemcitabine in combination with new platinum compounds: an update.
2001 Mar
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
2001 Mar
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.
2001 Mar
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
2001 Mar
Latent hematopoietic stem cell toxicity associated with protracted drug administration.
2001 Mar
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine].
2001 Mar
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
2001 Mar
Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer.
2001 Mar
Predictive molecular markers in non-small cell lung cancer.
2001 Mar
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
2001 Mar 15
Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells.
2001 Mar 23
Cotton-wool spots associated with pancreatic carcinoma.
2001 Mar 26
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition.
2001 May 4
Patents

Sample Use Guides

For intravenous use only. • Ovarian Cancer: 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.1) • Breast Cancer: 1250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.2) • Non-Small Cell Lung Cancer: 1000 mg/m2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.3) • Pancreatic Cancer: 1000 mg/m2 over 30 minutes once weekly for the first 7 weeks, then one week rest, then once weekly for 3 weeks of each 28-day cycle
Route of Administration: Intravenous
Treatment of PANC-1 cells with gemcitabine (10 nM) increased the percentage of cells in S phase to 60.1±6.0% and reduced the percentage in the G0/G1 phase to 28.7±4.2%
Name Type Language
GEMCITABINE
HSDB   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
GEMCITABINE [USAN]
Common Name English
LY188011
Code English
GEMCITABINE [MI]
Common Name English
GEMCITABINE [HSDB]
Common Name English
CYTIDINE, 2'-DEOXY-2',2'-DIFLUORO-
Systematic Name English
LY-188011
Code English
NSC-613327
Code English
GEMCITABINE [VANDF]
Common Name English
2'-DEOXY-2',2'-DIFLUOROCYTIDINE
Systematic Name English
gemcitabine [INN]
Common Name English
Gemcitabine [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QL01BC05
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
WHO-ATC L01BC05
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
NCI_THESAURUS C2150
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 504815
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 620917
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 477015
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
NDF-RT N0000000233
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 476915
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
NDF-RT N0000175595
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
LIVERTOX NBK548575
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 737820
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
FDA ORPHAN DRUG 502015
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
Code System Code Type Description
EVMPD
SUB07892MIG
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
SMS_ID
100000092349
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
HSDB
7567
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
WIKIPEDIA
GEMCITABINE
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
RXCUI
12574
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY RxNorm
MERCK INDEX
m5690
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY Merck Index
USAN
AA-12
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
CAS
95058-81-4
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
FDA UNII
B76N6SBZ8R
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
DRUG BANK
DB00441
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
INN
6515
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
LACTMED
Gemcitabine
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
PUBCHEM
60750
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
DRUG CENTRAL
1283
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
NSC
613327
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
NCI_THESAURUS
C66876
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
EPA CompTox
DTXSID3040487
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
DAILYMED
B76N6SBZ8R
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
ChEMBL
CHEMBL888
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
MESH
C056507
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
IUPHAR
4793
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY
CAS
103882-84-4
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
CHEBI
175901
Created by admin on Fri Dec 15 16:18:43 UTC 2023 , Edited by admin on Fri Dec 15 16:18:43 UTC 2023
PRIMARY